



26th July 2011

Lanthanum carbonate (Fosrenol®▼) tablets

The New Therapies Subgroup discussed the above drug at a meeting on the 20th November 2007 and 26th July 2011. The recommendation of this subgroup is as follows:*

The New Therapies Subgroup of the GMMMG considered the use of lanthanum carbonate (Fosrenol®▼) for the treatment of hyperphosphataemia for patients receiving dialysis.

The group recommends that lanthanum carbonate is used for the treatment of hyperphosphataemia for patients receiving dialysis only after at least one calcium-based phosphate binding agent has been tried including consideration of use of calcium acetate.

The group reminds prescribers that compared to the only other non-calcium phosphate binding agent used for long-term treatment (sevelamer, Renagel®▼), lanthanum carbonate is a more cost-effective treatment option after a daily dose of sevelamer 4.8 grams (6 tablets) has been reached.

Review date: July 2013

* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.

▼ Newly marketed drugs and vaccines are intensively monitored for a minimum of two years, in order to confirm the risk / benefit profile of the product. Healthcare professionals are encouraged to report all suspected adverse drug reactions regardless of the severity of the reaction.